- Atezolizumab (Tecentriq)
- Avelumab (Bavencio)
- Durvalumab (Imfinzi)

List above is copied verbatim from cancer.org.

University of Michigan - Ann Arbor

- PD-1 is a checkpoint protein on T cells (a type of immune cell).
- "When PD-1 binds to PD-L1, it basically tells the T cell to leave the other cell alone. Some cancer cells have large amounts of PD-L1, which helps them hide from an immune attack" (cancer.org).
- Checkpoint inhibitors that inhibit PD-1 and/or PD-L1 have great potential in battling certain cancers.
- Image from NIH - National Cancer Institute

Cancer Immunotherapy | Checkpoint Inhibitors against PD-1 and PD-L1

American Cancer Society

- Pembrolizumab (Keytruda)
- Nivolumab (Opdivo)
- Cemiplimab (Libtayo)

List above is copied verbatim from cancer.org

Learn Before

Related